Tenapanor (AZD1722) hydrochloride 是一种有效且具有口服活性的钠/氢交换异构体 3 (NHE3) (sodium/hydrogen exchanger isoform 3 (NHE3)) 抑制剂。Tenapanor hydrochloride 主要通过减少被动细胞旁磷酸盐通量来减少肠道对磷酸盐的吸收。Tenapanor hydrochloride 具有研究高磷血症的潜力。
生物活性 | Tenapanor (AZD1722) hydrochloride is a potent and orally activesodium/hydrogen exchanger isoform 3 (NHE3)inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia[1][2]. |
体内研究 (In Vivo) | Tenapanor hydrochloride (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats[1]. Tenapanor hydrochloride (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats[2].
Animal Model: | Rats (intestinal loop model)[1] | Dosage: | 0.15, 0.5 mg/kg | Administration: | P.o. | Result: | Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. |
Animal Model: | 8 weeks, 250 g male Sprague–Dawley rats[2] | Dosage: | 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) | Administration: | Oral gavage; twice-daily for 11 consecutive days | Result: | Significantly augmented the reduction in urinary phosphorus excretion. |
|
Clinical Trial | |
分子量 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |